|
|
|||
| Truvada |
Kivexa |
p-value |
|
|
|
|||
| Total number |
129 |
103 |
|
| Male |
119 (92.3%) |
96 (93.2%) |
0.78 |
| Female |
10 |
7 |
|
| Age (median, IQR) |
38 (32.43) |
38 (32.43) |
|
| Ethnicity |
|||
| African |
28 (21.7%) |
39 (37.9%) |
0.001 |
| Causcasian |
95 (73.6%) |
55 (50.5%) |
0.001 |
| Other |
6 (4.7%) |
12 (11.6%) |
0.001 |
| Smoker |
51 (42.5%) |
31 (30.4%) |
0.06 |
| History of cardiovascular event |
5 (3.9%) |
4 (3.9%) |
0.63 |
| Hypertensive |
9 (7.0%) |
13 (12.6%) |
0.14 |
| Diabetic |
3 (2.3%) |
6 (5.8%) |
0.14 |
| HBV co-infected |
13 (10.1%) |
1 (1.0%) |
0.02 |
| HCV co-infected |
1 (0.8%) |
4 (3.9%) |
0.27 |
| AIDS diagnosis |
26 (20.2%) |
19 (18.5%) |
0.74 |
| ART experienced |
63 (48.8%) |
53 (51.5%) |
0.74 |
| Current drug |
|||
| PI |
32 (24.8%) |
19 (18.5%) |
0.25 |
| NNRTI |
97 (75.2%) |
84 (81.6%) |
|
| Baseline laboratory markers |
|||
| CD4 (cells/mm3) median |
235 |
228 |
0.49 |
| Viral load (log copies/ml) median |
4.5 |
3.8 |
0.07 |
| Cholesterol (mmol/l) median |
4.3 |
4.5 |
0.05 |
| HDL (mmol/l) median |
1.1 |
1.2 |
0.52 |
| Triglyceride (mmol/l) median |
1.4 |
1.3 |
0.59 |
| GFR |
110 |
107 |
0.14 |
Eccleston et al. Journal of the International AIDS Society 2008 11(Suppl 1):P79 doi:10.1186/1758-2652-11-S1-P79 |
|||